The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …

Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized
by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible …

Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause
that has few treatment options. This disease was once thought to be a chronic inflammatory …

This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

… When the trials were combined by meta-analysis, pirfenidone attenuated the decline in 6MWD
by 25.2 m, whereas in the uILD trial the number of patients whose 6MWD declined by >50 …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …

… to identify or exclude pulmonary infection, especially M. tuberculosis in patients from endemic
areas with a high prevalence of M. tuberculosis, which can progress to death if untreated. …